Company* (Country; Symbol) |
Company (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
I. MODIFIED AGREEMENTS | |||
Argenta Discovery Ltd.* (UK) | Genentech Inc. (NYSE:DNA) | Contract drug discovery agreement extended for two more years | The project uses Argenta's expertise in computer-aided drug design, medicinal chemistry and in vitro biology and screening to discover new chemical entities acting against undisclosed targets (10/24) |
Dyax Corp. (DYAX) | ImClone Systems Inc. (IMCL) | Expanded antibody library collaboration giving ImClone access to Dyax's phage display technology for an additional four years | Dyax will continue to receive annual license fees as well as potential milestones and royalties (11/8) |
MorphoSys AG (Germany; FSE: MOR) | GeneFrontier Corp.* (Japan) | Collaboration that expands an existing alliance and aims to increase MorphoSys' access to druggable therapeutic targets from leading Japanese research institutes and universities | Financial details were not disclosed (12/11) |
II. TERMINATED AGREEMENTS | |||
Infinity Pharmaceuticals Inc. (INFI) | MedImmune Inc. (LSE:MDI; unit of Astra-Zeneca plc; UK) | Terminated agreement for the worldwide development and commercialization rights to Infinity's Hedgehog cell-signaling pathway inhibitor program, including its lead candidate IPI-926 | The deal was terminated because Med-Immune's parent company, AstraZeneca, has a competing program (11/12) |
Novavax Inc. (NVAX) | Allergan Inc. (NYSE:AGN) | Terminated manufacturing supply agreement for Estrasorb | Novavax will complete the manufacture of remaining orders and plans to close its Philadelphia manufacturing facility over the next few months (10/25) |
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. |